MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway

Qing Ling(Zhejiang Cancer Hospital), Jie Jin(Beijing Institute of Technology)

EBioMedicine

June 21, 2021

10.1016/j.ebiom.2021.103441

Cited by 20

Related Papers

Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6

|Proceedings of the National Academy of Sciences|2015|132

Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis

|PLoS ONE|2015|115

Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG.

|PubMed|2020|90

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

|Annals of Oncology|2023|82

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects

|EBioMedicine|2018|66